CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (Nasdaq Capital Market:ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has initiated a Phase 1b clinical study with Z944, its novel oral T-type calcium channel blocker, in an experimental clinical model of neuropathic pain using Laser-Evoked Potentials (LEP). Results from the LEP study are expected in the fourth quarter 2013. “Measuring Laser Evoked Potentials is an experimental clinical model that offers both subjective and objective measures to assess the potential of Z944 to modulate pain signaling,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “T-type calcium channels are known to be widely implicated in the frequency and intensity of pain signals and the results of this study will further inform Zalicus’ development plans for Z944 in a variety of potential indications as we work to optimize a modified release formulation of Z944 for future clinical trials.”
Help employers find you! Check out all the jobs and post your resume.
